Ellen Donnelly
Directeur Général chez ABLIVA AB
Postes actifs de Ellen Donnelly
Sociétés | Poste | Début | Fin |
---|---|---|---|
ALZECURE PHARMA AB | Directeur/Membre du Conseil | 01/01/2018 | - |
Independent Dir/Board Member | 01/01/2018 | - | |
MODUS THERAPEUTICS HOLDING AB | Directeur/Membre du Conseil | 01/01/2020 | - |
Independent Dir/Board Member | 01/01/2020 | - | |
Directeur Général | - | 01/01/2020 | |
ABLIVA AB | Directeur Général | 03/02/2021 | - |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Directeur/Membre du Conseil | 01/01/2019 | - |
Directeur Général | 01/01/2016 | 01/01/2019 |
Historique de carrière de Ellen Donnelly
Anciens postes connus de Ellen Donnelly
Sociétés | Poste | Début | Fin |
---|---|---|---|
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Corporate Officer/Principal | - | - |
Formation de Ellen Donnelly
Yale School of Medicine | Doctorate Degree |
Statistiques
Internationale
Suède | 5 |
Royaume-Uni | 2 |
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 3 |
Chief Executive Officer | 3 |
Independent Dir/Board Member | 2 |
Sectorielle
Health Technology | 5 |
Finance | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
ALZECURE PHARMA AB | Health Technology |
MODUS THERAPEUTICS HOLDING AB | Health Technology |
ABLIVA AB | Health Technology |
Entreprise privées | 2 |
---|---|
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Finance |
- Bourse
- Insiders
- Ellen Donnelly
- Expérience